VAC

BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Jul 11, 2007 - BioSantePharmaceuticals, Inc. (Amex: BPA) today announced new positiveresults demonstrating that its calcium phosphate (CaP)nanoparticle-based vaccine adjuvant, BioVant(TM), may serve as aneffective vaccine adjuvant for the development of a dose sparingvaccine against H5N1 avian flu, widely known as bird flu. The new results are based on...

DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC

MIAMI, FL -- (MARKET WIRE) -- July 06, 2007 -- DOR BioPharma,Inc. (OTCBB: <a target="_blank" href='http://studio.financialcontent.com/Engine?Account=iwire&PageName=QUOTE&Ticker=DORB"%3EDORB'>http://studio.financialcontent.com/Engine?Account=iwire&PageName=QUOTE&Ticker=DORB">DORB )("DOR" or the "Company") announced today that the European PatentOffice has granted a paten...

From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials

PHILADELPHIA, July 3, 2007-- Ongoing therapeutic cancer vaccinetrials have yet to show evidence of vaccines spurring apatient’s immune system to shrink tumors -- yet patients whoreceive these vaccines in trials tend to live longer and respondbetter to subsequent treatment. In the July 1 issue of ClinicalCancer Research, a journal of the American Association for CancerResearch, a te...

DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC

MIAMI--(MARKET WIRE) -- July 02, 2007 -- DOR BioPharma, Inc.(OTCBB: DORB) ("DOR" or the "Company") announced today that thefirst results from testing of a multivalent form of its botulinumtoxin vaccine, BT-VACC™, have been published in the journalInfection and Immunity (Ravichandran et al., 2007, Infection andImmunity, v. 75, p. 3043 ). These results are the first thatdescribe the...

Vaccine Can Prevent Cervical Cancer and Precancerous Lesions

LONDON, June 28, 2007--A cervical cancer vaccine has shown 90%efficacy for prevention of cervical cancer and precancerous lesionsassociated with the human papillomavirus (HPV) types targeted bythe vaccine, conclude authors of an Article published early Onlineand in the upcoming issue of The Lancet. HPV types 16 and 18 account for 70% or morecases of cervical cancer worldwi...

Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types

Results also show significant additional protection againstinfection with virus types beyond 16 and 18 with the GSK cervicalcancer candidate vaccine PHILADELPHIA, June 27, 2007 /PRNewswire-FirstCall/ -- Resultsfrom an interim analysis of a Phase III study show thatCERVARIX(R), the GlaxoSmithKline cervical cancer candidate vaccine,provides up to 100 percent protection against advanced prec...

Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

WORCESTER, Mass.--(BUSINESS WIRE)--Jun 28, 2007 - BiovestInternational, Inc. (OTCBB: BVTI), a majority owned subsidiary ofAccentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced on June27, 2007 blinded interim data from the start of its fast-trackedpivotal Phase 3 clinical trial of BiovaxID(TM) for Non-Hodgkin'slymphoma (NHL) from September 2000 through June 2006. This interimblinded dat...

HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference

BOSTON--(BUSINESS WIRE)--Jun 25, 2007 - HepaLife Technologies, Inc.(OTCBB: HPLF) (FWB: HL1) (WKN: 500625) today announced that newdata presented at an international influenza research conferencedemonstrates that HepaLife's patented PBS-1 cell line outperformscurrent cell technologies at replicating human influenza virusinside its cells. The most important step towards the production ofa cel...

New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus

HIGH WYCOMBE, UK 18th June 2007-Previously undisclosedpre-clinical data showing how a new flu vaccine has the potentialto protect against all strains of influenza, including pandemic andannual, was presented today by PepTcell, at the 2007 Options forthe Control of Influenza VI (Options) Conference, in Toronto,Canada. The pre-cli...

Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur

- Blood pressure reduction achieved at 8 am versus placebo: - 25/ - 13 mm Hg (systolic / diastolic, p - Blood pressure reduction dependent on vaccine dose and inducedantiangiotensin II antibody levels - Detailed results presented today at the Seventeenth EuropeanMeeting on Hypertension in Milan, Italy SCHLIEREN (Zurich), Switzerland and MILAN, Ita...

New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus

Data Presented at Leading Influenza Conference HIGH WYCOMBE, England, June 18, 2007 /PRNewswire/ -- Previouslyundisclosed pre-clinical data showing how a new flu vaccine has thepotential to protect against all strains of influenza, includingpandemic and annual, was presented today by PepTcell, at the 2007Options for the Control of Influenza VI (Options) Conference, inToronto, Canada....

Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007

HAMBURG, Germany, June 11, 2007 /PRNewswire/ -- NovaCardia, Inc.today presented preliminary results from a pilot Phase 3 trial ofKW-3902, an adenosine A1 receptor antagonist in development for thetreatment of patients with acute congestive heart failure (CHF),that indicate a strong trend toward efficacy for the 30 milligramdose. Patients treated with KW-3902 experienced a higher rate ofi...

Mymetics' HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model

NYON, Switzerland, June 07, 2007 /PRNewswire-FirstCall/ --Mymetics Corporation announced today analysis of resultsdemonstrating that the Company's HIV vaccine elicited neutralizingIgA mucosal antibodies in a non-human primate model. Mucosal IgAantibodies are considered as a possible first line of defenseagainst infection by HIV. The data were presented by SylvainFleury, Ph.D., Mymetics'...

Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting

SAN DIEGO--(BUSINESS WIRE)--Jun 6, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA vaccinesfor cancers and infectious diseases and a novel alternative tosurgery to treat localized cancers, announced today the companydelivered multiple presentations on preclinical study results andnew device innovations relating to its electroporation-mediated DNAdelivery te...

Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age

New Study Results Show Antibodies Against Cancer-Causing VirusTypes 16 & 18 That Are At Least Ten Times Greater Than NaturalInfection Levels CHICAGO, June 05, 2007 /PRNewswire/ -- New Phase III data showthat at 18 months after the first of a three-dose regimen, 100percent of women up to age 55 vaccinated with the GlaxoSmithKline(GSK) cervical cancer candidate vaccine had antibodies pr...

IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial

- Results show UVIDEM was well-tolerated with signs of durabledisease control in advanced melanoma patients - IRVINE, Calif., June 05, 2007 /PRNewswire-FirstCall/ -- IDMPharma, Inc. today presented preliminary results from a Phase IIUVIDEM (IDD-3) melanoma vaccine clinical trial (DC-MEL-202). Theresults showed that UVIDEM was well tolerated with evidence ofefficacy and induction of immune...

Pharmexa A/S (DK) - Long lasting immune response and survival to RAS vaccine

HORSOLM, Denmark, June 4, 2007-Professor Trond Buanes today gavea presentation titled "RAS peptide vaccination in resectedpancreatic cancer patients - persistence of anti tumour responseand long term survival" at ASCO's (American Society of ClinicalOncology) annual cancer meeting. A follow-up study of 23 resected pancreatic cancer...

Vakzine Projekt Management Reports Positive Clinical Trial Results With Their Therapeutic Prostate Cancer Vaccine VPM4001

HANOVER, Germany--(BUSINESS WIRE)--Jun 1, 2007 - A therapeuticvaccine developed by the German company VPM to battle prostatecancer promises new hope for cancer patients. The results of asuccessfully completed clinical study will be presented to aninternational audience at the Annual Conference of the AmericanSociety for Clinical Oncology (ASCO) in Chicago, USA. ASCO is themost important pro...

Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal Challenge of Live Virus, Pre-Clinical Data Show

Study Presented at Second International Conference on AvianInfluenza at France's Pasteur Institute PARIS, June 01, 2007 /PRNewswire-FirstCall/ -- Very low doses ofNovavax Inc.'s pandemic influenza vaccine provided protectionagainst a lethal challenge of live H5N1 viruses, according topre-clinical data presented here today at the Second InternationalConference on Avian Influenza in Humans....

Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates

SEATTLE, May 31, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that a measles DNA vaccine formulatedwith the company's Vaxfectin(TM) adjuvant elicited protectivelevels of neutralizing antibodies in juvenile (1 - 2 year old)nonhuman primates confirmed by complete protection followingchallenge more than one year after vaccination, and sterilizingimmunity as evidenced by...

Generex Biotechnology Vaccine Strategy Presented at International Conference in London

WORCESTER, MA - May 24, 2007 - Generex Biotechnology Corporation(NasdaqCM:GNBT) announced today that Dr. Douglas Powell, Directorof Immunobiology at its wholly-owned Antigen Express subsidiary,has presented Antigen's vaccine development strategy at aninternational conference in London, UK. The international meeting,"Developing New Anti-Infective Agents - Challenges andOpportunities" (<a...

VGX Pharmaceuticals' Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models

MALAGA, Spain--(BUSINESS WIRE)--May 23, 2007 - VGX Pharmaceuticals'novel pandemic influenza vaccine candidates triggered protectiveimmune responses in pre-clinical challenge studies, according todata presented for the first time today at the Third InternationalConference on DNA Vaccines in Malaga, Spain. VGX scientists created four synthetic consensus DNA vaccines toprotect against a leth...

CytoGenix to Present at 2007 International DNA Vaccines Conference in Spain

HOUSTON--(BUSINESS WIRE)--May 23, 2007 - CytoGenix, Inc. (CYGX.OB)announced today that Dr. Yin Chen, Chief Scientific Officer willpresent an update on preclinical animal data for DNA vaccines madeusing the Company's proprietary synDNA(TM) technology at the 2007DNA Vaccines conference to be held in Malaga, Spain between May 23and May 25. Dr. Chen comments, "We have successfully conducted t...

Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues

MALAGA, Spain, May 23, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that in a recently completed animalstudy, a DNA vaccine formulated with the company's patentedVaxfectin(TM) adjuvant and delivered by needle-free injectionyielded significantly higher antibody responses than anunformulated DNA vaccine delivered by needle and syringe. In aseparate animal study, electro...

FDA MedWatch: Avastin (bevacizumab) and Formation of Tracheoesophageal Fistula in a Recent Clinical Study in Patients with Limited-stage Small Cell Lung Cancer

ROCKVILLE, Md., April 21, 2007-Genentech and FDA notifiedhealthcare professionals of important new safety informationregarding tracheoesophageal (TE) fistula formation in a recentclinical study in patients with limited-stage small cell lungcancer (SCLC). This multicenter, non-randomized, single-arm phaseII clinical trial study combined chemotherapy and radiation plusAvastin. There have b...

Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free Survival by 45 Percent in Patients With Intermediate-Risk Kidney Cancer

ANAHEIM, Calif.--(BUSINESS WIRE)--May 21, 2007 - Antigenics Inc.(NASDAQ: AGEN) today announced additional follow-up data on thecompany's Phase 3 investigational therapeutic cancer vaccineOncophage(R) (vitespen). The end-of-study results, which reflect anadditional 17 months' data collection, showed that in a substantialsubset of patients (n = 362) at intermediate risk for diseaserecurrence,...

Avant’s Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential

Single-Dose Oral Ty800 Vaccine Immunogenic & Well-Toleratedin NIH-Sponsored Phase 1/2 Study NEEDHAM, MA (May 18, 2007) - AVANT Immunotherapeutics, Inc.(Nasdaq: AVAN) announced today positive preliminary results from aninvestigational double-blind, placebo-controlled Phase 1/2dose-escalating clinical trial of its typhoid fever vaccinecandidate, Ty800, in healthy volunteers. The...

Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials

VIENNA, Austria, May 18, 2007 – Intercell AG (VSE,“ICLL”) has been informed by its strategic partnerMerck & Co., Inc. on the results of a Phase I study involvingin total over 120 adult healthy volunteers comparing safety andimmunogenicity of different doses of the Staphylococcus aureusvaccine. The Staphylococcus aureus vaccine is based on a conserved prote...

Avant's Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential

NEEDHAM, Mass.--(BUSINESS WIRE)--May 18, 2007 - AVANTImmunotherapeutics, Inc. (Nasdaq: AVAN) announced today positivepreliminary results from an investigational double-blind,placebo-controlled Phase 1/2 dose-escalating clinical trial of itstyphoid fever vaccine candidate, Ty800, in healthy volunteers. Theresearchers found the single-dose, oral vaccine to be welltolerated and immunogenic, wi...

GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines

Investigational vaccine could offer protectionfor infants against type b andmeningococcal disease — GlaxoSmithKline (GSK) announced results from aPhase II vaccine clinical study presented this week at thePediatri...

New England Journal of Medicine Publishes New Data on Gardasil, Merck's Cervical Cancer Vaccine

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-May 10, 2007--Today, theNew England Journal of Medicine is publishing results from twoPhase III studies of Merck's cervical cancer vaccine, Gardasil(Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18)Recombinant Vaccine). In the first study, Gardasil provided 100percent protection against cervical, vaginal and vulvar diseasescaused by the four H...

Revolutionary Immunologic Data Explains Function of Diamyd Diabetes Vaccine

Diamyd Medical AB (<a target="_blank" href="http://www.omxgroup.com/">www.omxgroup.com ticker: DIAM B; ticker DMYDY) STOCKHOLM, Sweden, May 3, 2007 – During a presentationmade in Linkoping, Sweden at the Sweden-Seattle Diabetes Conferencethis past week-end, Professor Johnny Ludvigsson, the Principal...

Novavax Reports Positive Pre-Clinical Study Results from Live Virus Challenge to Pandemic Flu Vaccine

Ferret Study to be Part of Data Package Required to Begin ClinicalTrials ROCKVILLE, Md., May 03, 2007 /PRNewswire-FirstCall/ -- NovavaxInc. said today that it has received positive study results from alive virus challenge to ferrets inoculated with its pandemicinfluenza vaccine, paving the way for clinical trials to begin onschedule later this year. In the study, ferrets were inocu...

Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than Vaccines Used in Previous Years

ROCHESTER, N.Y., May 02, 2007 /PRNewswire/ -- A new Harris Pollsuggests that the flu vaccine used before last winter may have beenless effective than the vaccines used in some previous years. Theadults who had flu shots before last winter were only 24 percentless likely to get the flu than those who were not vaccinated. Thedifferences were larger in two previous Harris Polls on the samet...

Apollo develops needle-free topical vaccine

SYDNEY, April 30, 2007-Australian bio-discovery company ApolloLife Sciences has released results of preliminary trials of itspatented needle-free vaccine technology, which delivers tetanusvaccine transdermally (through the skin) without the need for aninjection. According to Apollo CEO John Priest, the research points the wayto the possibility that flu injections may soon be a thin...

Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for Travelers' Diarrhea Stimulates Immune Response Even at Low Doses

-- Data Gathered to Assist in Design of Future Trials, OtherPrograms -- GAITHERSBURG, Md. and LISBON, Portugal, April 26, 2007/PRNewswire-FirstCall/ -- Iomai Corporation today announced resultsfrom a 400-patient, Phase 2 dose-ranging trial of its patch-basedvaccine for travelers' diarrhea. The trial was conducted to assessthe ability of a range of vaccine doses to generate an immunerespo...

Data Presented at AACR Meeting Show Peregrine's Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer

--Immunization with a Bavituximab Equivalent and Irradiated TumorCells Increased Long-Term Survival to 57% From 0% in Controls in aPreclinical Model of Brain Cancer-- LOS ANGELES and TUSTIN, Calif., April 18, 2007/PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , aclinical stage biopharmaceutical company developing targetedmonoclonal antibodies for the treatment of cancer and hep...

Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years

New study results also show evidence of additional protectionagainst infection with other cancer-causing virus types LOS ANGELES, April 17, 2007 /PRNewswire-FirstCall/ -- TheGlaxoSmithKline cervical cancer candidate vaccine, CERVARIX(R),demonstrated 100 percent efficacy in preventing precancerouslesions due to cancer-causing human papillomavirus types 16 and 18for up to 5.5 years in an ex...

Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine in Glioma Presented at American Association of Neurological Surgeons Annual Meeting

WASHINGTON--(BUSINESS WIRE)--Apr 16, 2007 - Antigenics Inc.(NASDAQ: AGEN) today announced an oral presentation of updated datafrom a Phase 1/2 investigator-sponsored trial of the company'sinvestigational cancer vaccine Oncophage(R) (vitespen) inrecurrent, high-grade glioma at the 75th annual meeting of theAmerican Association of Neurological Surgeons (AANS; abstract#606). Preliminary result...

Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine

SAN FRANCISCO, April 11, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that a seasonal influenza vaccineformulated with the company's Vaxfectin(TM) adjuvant generated upto 60-fold higher antibody responses than an unformulated vaccineat the same dose in a recently completed study in mice. Formulationof sanofi pasteur's Fluzone(R) commercial vaccine withVaxfectin(TM) al...